Lv11
40 积分 2023-06-12 加入
Re-Evaluating Antibody–Drug Conjugate Linker Stability: Assessment, Interpretation, and Clinical Translation
2小时前
待确认
Clinicopathological features of breast cancer with different molecular subtypes in chinese women
4天前
已完结
Global Stage Distribution of Breast Cancer at Diagnosis
4天前
已完结
SELECT: A Phase II Trial of Adjuvant Erlotinib in Patients With Resected Epidermal Growth Factor Receptor–Mutant Non–Small-Cell Lung Cancer
16天前
已完结
Adjuvant Erlotinib Versus Placebo in Patients With Stage IB-IIIA Non–Small-Cell Lung Cancer (RADIANT): A Randomized, Double-Blind, Phase III Trial
16天前
已完结
Can Women With HER2-Positive Metastatic Breast Cancer Be Cured?
18天前
已完结
Osimertinib plus datopotamab deruxtecan in patients with EGFR-mutated advanced NSCLC post-progression on first-line osimertinib: ORCHARD
2个月前
已完结
Efficacy and Safety of Ultra-Low-Dose Immunotherapy in Relapsed Refractory Solid Tumors: Phase III Superiority Randomized Trial (DELII)
3个月前
已完结
Izalontamab brengitecan (Iza-bren; BL-B01D1), a first-in-class EGFR-HER3 bispecific antibody–drug conjugate, for patients with EGFR-mutated NSCLC: Pooled analysis of phase 1 and phase 2 trials
3个月前
已关闭
TBCRC 048 (Olaparib Expanded) Expansion Cohorts: Phase II Study of Olaparib Monotherapy for Patients With Metastatic Breast Cancer With Germline Mutations in PALB2 or Somatic Mutations in BRCA1 or BRCA2
3个月前
已关闭
皖公网安备34019202002308
